Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Forkhead box protein E3 (FOXE3)
- Target
- FOXE3
- Molecular classification
- Transcription factor, Forkhead box (FOX) family
01
Overview
Forkhead box protein E3 (FOXE3) is a member of the forkhead box (FOX) family of transcription factors characterized by a conserved forkhead/winged-helix DNA-binding domain[1][3][5][8]. FOXE3 is expressed predominantly in the developing lens of the vertebrate eye, where it plays an essential role in the formation and maintenance of lens epithelial cells, regulation of cell proliferation, apoptosis, and lens fiber differentiation[1][3][5][6][9]. FOXE3 mutations can disrupt lens morphogenesis, leading to various congenital ocular diseases such as anterior segment dysgenesis, cataracts, and aphakia[1][3][5][8][9]. Both dominant and recessive FOXE3 gene variants have been found in human ocular pathologies. The protein acts upstream of key developmental regulators during eye formation and is considered critical rather than a conventional druggable therapeutic target.
- Other names
- FKHL12FREAC8FREAC-8forkhead-related transcription factor 8forkhead-related protein FKHL12AAT11ASGD2CATC3CTRCT34
02
Biological functions
Regulation of lens developmentRegulation of cell proliferation and apoptosis in lens epithelial cellsCell cycle controlDNA-binding transcription factor activity (RNA polymerase II-specific)Negative regulation of lens fiber cell differentiation
03
Disease associations
Anterior segment dysgenesis (including anterior segment mesenchymal dysgenesis)Congenital primary aphakiaCataract (including congenital cataracts and Cataract 34, multiple types)MicrophthalmiaPeters anomalySclerocorneaOptic disc coloboma
04
Safety considerations
Not a direct therapeutic target, so no notable drug safety concerns reported. Genetic mutations are associated with severe developmental eye diseases, which may limit potential for direct pharmacological targeting due to the critical role in eye development.
05
Biomarkers
Mutations in FOXE3 gene for congenital ocular disorders (e.g., anterior segment mesenchymal dysgenesis, Peters anomaly, congenital aphakia) [1][3][5][8]
Beyond the preview
Go deeper on Forkhead box protein E3 (FOXE3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Forkhead box protein E3 (FOXE3).